Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 24;61(1):70.
doi: 10.1186/s42358-021-00228-x.

Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Karina Rossi Bonfiglioli  1 , Licia Maria Henrique da Mota  2 , Ana Cristina de Medeiros Ribeiro  3 , Adriana Maria Kakehasi  4 , Ieda Maria Magalhães Laurindo  5 , Rina Dalva Neubarth Giorgi  6 , Angela Luzia Branco Pinto Duarte  7 , Ana Paula Monteiro Gomides Reis  2 , Mariana Peixoto Guimarães Ubirajara E Silva de Souza  8 , Claiton Viegas Brenol  9 , Geraldo da Rocha Castelar Pinheiro  10 , Cleandro Pires de Albuquerque  2 , Charlles Heldan de Moura Castro  11 , Gustavo Luiz Behrens Pinto  12 , Jose Fernando Verztman  13 , Luciana Feitosa Muniz  14 , Manoel Barros Bertolo  15 , Maria Raquel da Costa Pinto  4 , Paulo Louzada Júnior  16 , Vitor Alves Cruz  17 , Ivanio Alves Pereira  18 , Max Vitor Carioca de Freitas  19 , Bóris Afonso Cruz  20 , Eduardo Paiva  21 , Odirlei Monticielo  9 , José Roberto Provenza  22 , Ricardo Machado Xavier  9
Affiliations
Review

Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Karina Rossi Bonfiglioli et al. Adv Rheumatol. .

Abstract

Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.

PubMed Disclaimer

References

    1. Mota LMHD, Kakehasi AM, Gomides APM, et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol. 2018;58(1):2. https://doi.org/10.1186/s42358-018-0005-0 . - DOI - PubMed
    1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatologycriteria: a systematic review. Semin Arthritis Rheum. 2006;36:182–8. - PubMed
    1. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54:944–7. - PubMed - PMC
    1. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol. 2007;21:929–42. - PubMed
    1. Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol. 2009;21:291–8. - PubMed

Publication types

LinkOut - more resources